Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel)

PRINCETON, N.J.--(BUSINESS WIRE) November 16, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that its review of the Biologics License Application (BLA) for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials